Moreover as Foxa1 is repressed in NAFL, its pharmacological activation could counteract lipid deposition, and could prove useful for the therapy and prevention of NAFLD and insulin resistance. This evidence concerns the gene FOXA1 and metabolic dysfunction-associated steatotic liver disease.